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SalmonellaCurrent antibiotic testing does not include the potential influence of host cell environment on microbial suscep-
tibility and antibiotic resistance, hindering appropriate therapeutic intervention. We devised a strategy to iden-
tify the presence of host–pathogen interactions that alter antibiotic efficacy in vivo. Our findings revealed a
bacterialmechanism that promotes antibiotic resistance in vivo at concentrations of drug that far exceed dosages
determined by standardized antimicrobial testing. This mechanism has escaped prior detection because it is
reversible and operates within a subset of host tissues and cells. Bacterial pathogens are thereby protected
while their survival promotes the emergence of permanent drug resistance. This host-dependent mechanism
of transient antibiotic resistance is applicable to multiple pathogens and has implications for the development
of more effective antimicrobial therapies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent CDC estimates indicate that one in five pathogens from
hospital-acquired infections in the U.S. are multidrug-resistant (Kallen
et al., 2010; Sievert et al., 2013), dramatically limiting therapeutic
options to antibiotics that may bemore toxic, less effective, or more ex-
pensive (Centers for Disease Control and Prevention, 2013). In such
cases, patients often have longer hospital stays, delayed recuperation,
long-term disability, and increased mortality. Deciphering the mecha-
nisms that govern the emergence of multidrug-resistant pathogens is
critical to the development of new approaches to control bacterial infec-
tions. Many mechanisms of antibiotic resistance have been established,
including horizontal gene transfer; genomic mutation; and intrinsic
bacterial mechanisms that pre-date antibiotics (Allen et al., 2010;
Andersson and Hughes, 2010; Cox and Wright, 2013; D'Costa et al.,
2011; Davies and Davies, 2010). Significant advances have been made
regarding the generation of antibiotic resistant variants (phenotypic
and genotypic) that emerge during infection; e.g., Staphylococcus aureusar and Developmental Biology,
Mahan).
. This is an open access article undersmall colony variants that promote persistent infections (Proctor et al.,
2006); antibiotic resistance of Pseudomonas aeruginosa biofilms
(Høiby et al., 2010); the evolution and spread of multidrug-resistant
pneumococcal variants (Croucher et al., 2011), and heteroresistant sub-
populations of vancomycin-susceptible S. aureus (El-Halfawy and
Valvano, 2015). Despite this knowledge, the role of host–pathogen in-
teractions in antibiotic resistance is poorly understood, and the use of
host models as a primary approach to understanding resistance is not
often considered or explored.
For the past several decades, drug development has followed a stan-
dard sequential procedure wherein: (i) efficacy is determined in vitro;
(ii) pharmacokinetic/pharmacodynamic (PK/PD) parameters are mea-
sured in vivo; and (iii) dosing efficacy/toxicity in vivo is established for a
limited number of model pathogens (Ambrose et al., 2007; Clinical and
Laboratory Standards Institute, 2012; Food and Drug Administration,
2009). However, along with a limited amount of patient-dosing data,
physicians rely on in vitro antimicrobial susceptibility testing (AST) of
clinical isolates grown on the universal media standard Mueller–Hinton
Broth (MHB) for therapeutic intervention (Clinical and Laboratory
Standards Institute, 2012; European Committee on Antibiotic
Suscepibility Testing, 2014). This standard procedure does not replicate
mammalian biochemistry and may not correlate with patient outcome.
To overcome these limitations, we investigated antibiotic resistance in
the context of animalmodels of disease, and have identified amechanismthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion, while promoting the emergence of drug-resistant bacteria.
2. Materials and Methods
2.1. Bacterial Strains and Media
TIVAR+ S. Typhimurium ATCC 14028 (CDC 6516–60) and MT2057
(an isogenic KAN resistant derivative of 14028), or TIVAR− S.
Typhimurium var. 5 (04)-9639 (a multidrug-resistant isolate) derived
from chicken and cow, respectively, were used in these studies
(Conner et al., 1998; Heithoff et al., 2008). These strains have identical
oral and i.p. lethal dose 50s (LD50) in BALB/c mice, 105 and b10 colony
forming units (CFU), respectively (Heithoff et al., 2008). Salmonella
human clinical isolates were obtained from fecal and blood samples
derived from patients with gastroenteritis or bacteremia, respectively;
animal isolates were derived from different disease outbreaks, individ-
ual cases, or surveillance submissions to diagnostic laboratories
(Heithoff et al., 2008). Unless otherwise specified, Salmonellawere de-
rived from stationary phase cultures aerated at 37 °C containing the
Mueller–Hinton broth (MHB) (Clinical and Laboratory Standards
Institute, 2012); low phosphate, low magnesium medium (LPM)
(Coombes et al., 2004) or N-minimal medium (Nelson and Kennedy,
1971) supplemented with 0.3% glycerol and 0.1% casamino acids; or
the Luria–Bertani (LB) medium (Davis et al., 1980). Yersinia pseudotu-
berculosis IP32953 is a virulent human isolate (Chain et al., 2004), and
was assayed from stationary phase cultures aerated at 28 °C containing
MHB or LPM media.
2.2. MIC Assays
The minimum inhibitory concentration (MIC) was determined in
MHB and LPM media (pH 7 and pH 5.5) according to Clinical and
Laboratory Standards Institute (CLSI) guidelines (Clinical and
Laboratory Standards Institute, 2012; Wiegand et al., 2008). MIC as-
says were performed on bacteria obtained from overnight culture,
and from bacteria derived from macrophage lysates or host tissues.
Bacteria were diluted in 0.15 M NaCl, and a 5 μl volume containing
104 CFU was spotted on agar plates of the media condition indicated,
containing two-fold dilutions of each antibiotic. MIC values were de-
rived following 20 h incubation at 37 °C (Salmonella) or 48 h incuba-
tion at 28 °C (Y. pseudotuberculosis), and were the result of at least
three independent determinations.
2.3. Bacterial Cell Survival Assays
Bacterial cell survival was evaluated after cells derived from a given
growth condition were exposed to antibiotics under the same or differ-
ent growth condition (Groisman et al., 1997). S. Typhimurium 14028
was grownovernight in non-inducingmedium for the TIVARphenotype
(N-minimalmediumwith 10mMMg2+ pH 7.7), diluted 1:100 in either
inducing medium (N-minimal medium with 10 μM Mg2+ pH 5.8) or
non-inducing medium (N-minimal medium with 10 mM Mg2+
pH 7.7), and incubated 4 h at 37 °C. Bacteria were diluted 1:200 and ex-
posed to polymyxin B for 1 h in either inducing medium (N-minimal
medium with 10 μMMg2+ pH 5.8) or non-inducing medium (LB), and
plated for CFU on LB medium. Percent survival was calculated as CFU
[polymyxin B] / CFU[no drug] × 100 at 1 h post drug exposure; values given
are the REMLmodel means± SEM derived from at least 5 independent
determinations.
2.4. Virulence Assays
Intraperitoneal (i.p.) infection. Salmonella grown overnight in LB me-
dium were resuspended in 0.15 M NaCl and administered to mice via
the i.p. route of infection (dose 102 or 103 CFU) (Heithoff et al., 1999).Five days post-infection, the bacterial cells were recovered from the
spleen and other tissues/fluids of acutely infected animals. Antibiotic
treatment. Mice infected i.p. with Salmonella (i.p. dose 102 CFU) were
treated (or mock-treated) with a twice-daily polymyxin B or ciproflox-
acin dosing regimen (30 mg/kg/day). Bacterial cells were recovered
from the spleen of acutely infected animals and enumerated by direct
colony count. Mouse survival was assessed for 10 days post-infection.
Uninfected mice were also treated with polymyxin B to control for dos-
ing toxicity. Six- to twelve-week old female BALB/c mice were used in
all virulence studies. Institutional Animal Care and Use Committee of
the University of California, Santa Barbara approved all mouse research
protocols undertaken herein.
2.5. Cell Culture
The murinemacrophage cell line RAW 264.7 was obtained from the
American Type Culture Collection, Rockville, MD., and maintained in
minimum essential medium (MEM) supplemented with L-glutamine
and 10% heat-inactivated bovine growth-supplemented calf serum
(HyClone Laboratories, Logan, UT). Cells were grown in a humidified at-
mosphere of 5% carbon dioxide and 95% air at 37 °C in 75-cm2 plastic
flasks (Corning Glass Works, Corning, NY). Cultured murine macro-
phages (RAW 264.7) were harvested by scraping with a rubber police-
man and plated at a density of 2.5 to 5 × 105 cells/ml in 4 ml of culture
medium in 35 mm-diameter, six-well dishes (Corning) and grown for
24 h to approximately 80 to 90% confluence (1 to 5 × 106 cells/well)
(adapted from previous methods (Fleckenstein et al., 1996)).
2.6. Bacterial Infection of Cultured Murine Macrophages
Bacterial cells were used to infect cultured murine macrophage
(RAW 264.7) monolayers grown in cell culture plates (Corning) at a
multiplicity of infection (MOI) of 10:1. The bacteria were centrifuged
onto cultured monolayers at 1000 ×g for 10 min at room temperature,
after which they were incubated for 30min at 37 °C in a 5% CO2 incuba-
tor. The co-culture was washed once with cell culture medium and in-
cubated for 45 min in the presence of gentamicin (100 μg/ml) to kill
extracellular bacteria, washed oncewith pre-warmed cell culturemedi-
um, and incubated in 4ml of culturemedium containing polymyxin B at
the concentration indicated or 10 μg/ml gentamicin (t= 0 time point)
for 24 h (adapted from previous methods (Finlay and Falkow, 1988)).
2.7. Statistical Analyses
Log transformed intracellular CFU and PMBr mutation frequency
data were analyzed using ANOVA (ANOVA, GenStat, 15th Edition, VSN
International, UK). Intracellular CFU and PMBr mutation frequency
data are presented as the means ± standard error of the mean (SEM).
Cell survival was analyzed using residual (or restricted)maximum like-
lihood (REML) analysis (GenStat, 15th Edition, VSN International, UK). A
single variate model was used to analyze percentage survival on a log
scale. The fixed effects of the model were the factors group, drug con-
centration, and their interaction. The Wald chi-square test was used to
determine significant main effects and/or significant interactions be-
tween factors. Any non-significant terms were dropped from the
model and analysis repeated. Following analysis, data are presented as
predicted model-based means, i.e., predicted means are those obtained
from the fitted model rather than the raw sample means. Differences
between the individual means calculated using ANOVA and REML
were determined by calculating an approximate least significant differ-
ence (LSD). A difference of means that exceeded the calculated LSDwas
considered significant. Statistical significance for difference in propor-
tions of animal survival was calculated using Chi-square (Epi Info 7,
CDC). For all statistical analyses, a significance level (P) of less than
0.05 was considered to be statistically significant. Degrees of statistical
significance are presented as ***P b 0.001, **P b 0.01, or *P b 0.05.
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3.1. Bacteria Exhibit High-level Antibiotic Resistance under Conditions That
Simulate Host Microenvironments
The biochemical environment within certain host sites may induce
transient changes in the bacterium that confer resistance to antibiotics.
Thus, we screened a collection of pathogenic strains for antibiotic resis-
tance under experimental conditions that simulated hostmicroenviron-
ments, including those present in the macrophage phagosome, a sub-
cellular organelle in which Salmonella resides and replicates (Steele-
Mortimer, 2008). Conditions within the phagosome can be mimicked
by mildly acidic culture medium (pH 5.5) that is low in phosphate and
magnesium (LPM) (Coombes et al., 2004). We compared the efficacy
of 16 clinically-relevant antibiotics against Salmonella grown in LPM
pH 5.5medium versus that grown inMHB (unbuffered ~ pH 7.2) via as-
sessment of the minimum inhibitory concentration (MIC) of each anti-
biotic (Clinical and Laboratory Standards Institute, 2012; European
Committee on Antibiotic Suscepibility Testing, 2014). To control for
the potential effects of pH and media composition, antibiotic resistance
was determined by comparing the MICs in LPM medium versus those
obtained in MHB at pH 5.5 and pH 7.
Growth of S. enterica Typhimurium in LPM pH 5.5 medium was
linked to high-level resistance to polymyxin B (PMB; 64-fold) andFig. 1. Salmonella and Yersinia exhibit high-level antibiotic resistance under conditions that simu
Hinton Broth (MHB) (Clinical and Laboratory Standards Institute, 2012) or low phosphate, low
inhibitory concentration (MIC) of a panel of antibioticswas determined in the samemedium (C
conditions on antibiotic resistance was calculated by comparing the MIC in LPMmedium divide
pH 7.0 to MHB pH 5.5/pH 7.2). Drugs: polymyxin B, PMB; colistin sulfate, CST; trimethoprim, T
cycline, TCN; chloramphenicol, CAM; florfenicol, FFC; ampicillin, AMP; ceftriaxone, CTX; cef
Y. pseudotuberculosis IP32953 susceptibility to antibiotics as a function of growth conditions. Mcolistin (CST; 256-fold), cationic peptides that disrupt Gram-negative
membranes (Bergen et al., 2012; Landman et al., 2008) (Fig. 1A). We
also observed a mild resistance to trimethoprim (TMP; 4-fold), an in-
hibitor of folate metabolism (Burchall, 1973). Under these conditions,
Salmonella remains viable, and continues to grow at antibiotic concen-
trations that far exceed those achieved in treating human infections
(0.5 to 2.5 mg/l) (Michalopoulos and Falagas, 2011; National
Institutes of Health, 2014b; Sandri et al., 2013; Zavascki et al., 2008).
Some other antibiotics examinedwere subject to pH and/ormedia com-
position effects on drug efficacy including kanamycin, streptomycin,
and ciprofloxacin. In those cases, we could not determine the induction
of antibiotic resistance. In other cases the efficacy of antibiotics was
altogether unaffected, including tetracycline, chloramphenicol, and
ceftiofur. Many pathogenic Salmonella serovars (serotypic variants) de-
rived from human and livestock infections (Heithoff et al., 2008) exhib-
ited high-level resistance to antibiotics PMB, CST and TMPwhen grown
in LPM pH 5.5 medium: S. Typhimurium (5/6), S. Enteritidis (1/1), S.
Dublin (2/2), S.Newport (1/2), S. Bovismorbificans (1/2), and Salmonel-
la C1 K00-670 (1/1) (Supplementary Table 1). These data indicate that
induction of antibiotic resistance under conditions simulating the
phagosome is not a strain-specific phenomenon.
To ascertain whether the induction of antibiotic resistance exists
in other microbial species, we screened for this phenotype in
Y. pseudotuberculosis, a Gram-negative extracellular pathogen thatlate hostmicroenvironments. (A) S. Typhimurium14028was grown in either theMueller–
magnesiummedium (LPM) (Coombes et al., 2004) at the pH indicated, and the minimum
linical and Laboratory Standards Institute, 2012;Wiegand et al., 2008). The effect of growth
d by theMIC inMHBmedium at both pH 5.5 and pH 7 (unbuffered) (ratio of LPM pH 5.5/
MP; sulfamethoxazole, SMX; kanamycin, KAN; neomycin, NEO; streptomycin, STR; tetra-
tiofur, CEF; nalidixic acid, NAL; ciprofloxacin, CIP; enrofloxacin, EFX. (B) The degree of
IC values were obtained from at least 3 independent determinations.
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2011; Tauxe, 2013). After normalizing for pH andmedia composition
effects on drug efficacy, Y. pseudotuberculosis acquired increased
resistance not only to antibiotics PMB, CST, and TMP (32-fold, 16-fold,
and 4-fold, respectively), but also to sulfamethoxazole (SMX)
(16-fold), another inhibitor of folate metabolism (National Institutes
of Health, 2014a) (Fig. 1B; Supplementary Table 2). Further, the induc-
tion of Yersinia antibiotic resistance occurred under markedly different
environmental conditions compared to Salmonella (in MHB pH 5.5 but
not in LPM pH 5.5), perhaps reflecting the dissimilar host intracellular
and extracellular trafficking of these bacterial species (Salmonella expo-
sure to defensins within the phagosome (Steele-Mortimer, 2008);
Yersinia exposure to cryptdins in the small intestine (Bevins and
Salzman, 2011)). Together, these findings suggest that the scope of
resistance inductionmay include a variety of different species; and cur-
rentmethods used to assess the degree and spectrumof antibiotic resis-
tance do not account for environmental influences on microbial
susceptibility in vivo.
3.2. Phenotypic Switching to High-level Antibiotic Resistance Is Rapid and
Rapidly Reversible
To understand the mechanistic nature of phenotypic switching be-
tween antibiotic susceptible to resistant states, the kinetics and degreeFig. 2. Induction of high-level antibiotic resistance in Salmonella is rapid and rapidly reversible
grown for 4 cell generations (cell doublings) in MHB (log phase) and transferred to LPM pH 5.5
medium for 7 cell generations (Heithoff et al., 2012). (B) S. Typhimurium 14028 was grown o
without dilution to LPM pH 5.5 medium. MIC values were determined in LPM pH 5.5 medium
of growth conditions prior to and during drug exposure on Salmonella susceptibility to poly
grown (4 h) under inducing (I) or non-inducing (NI) conditions for TIVAR were subsequently
medium. Black bars (I/I), growth and drug exposure (N-minimal medium with 10 μMMg2+
exposure (LB). Gray bars (NI/I), growth (N-minimal medium with 10 mM Mg2+ pH 7.7); drug
(N-minimal mediumwith 10mMMg2+ pH 7.7); drug exposure (LB). Percent survival = CFU[p
vival was analyzed using REML analysis. Values given are the REML model means ± SEM derivof antibiotic resistance induction was evaluated upon transfer of bac-
terial cells from MHB (non-inducing) to LPM pH 5.5 (inducing) me-
dium. For this analysis, comparisons were made between a natural
Salmonella isolate that was capable of inducing high-level resistance
(S. Typhimurium 14028), with one that was not (S. Typhimurium var. 5
(04)-9639) (Supplementary Table 1). Transfer of S. Typhimurium
14028 fromMHB to LPM pH 5.5medium resulted in a rapidMIC change
from a PMB susceptible to resistant phenotype within 1 cell doubling
(Fig. 2A). Upon subsequent transfer from LPM pH 5.5 back to MHBme-
dium, bacteria reverted to the susceptible phenotype within 4 to 5 gen-
erations. In contrast, transfer of S. Typhimurium var. 5 (04)-9639 from
MHB to LPMpH5.5mediumdid not result in high-level PMB resistance.
These data indicate that, for isolates capable of resistance induction,
phenotypic switching to high-level antibiotic resistance is rapid and
rapidly reversible. We then examined whether resistance induction
can occur in the absence of rapid cell division and mutational selection
via transferring bacterial cells from an overnight MHB culture into LPM
pH 5.5medium. It is anticipated that such amedia shift markedly slows
bacterial cell division since the final cell density of a saturated culture in
rich MHB medium is considerably greater (~5-fold) than that in LPM
pH 5.5 medium (Heithoff et al., 2012). Transfer of S. Typhimurium
14028 from MHB to LPM pH 5.5 medium, without dilution, resulted in
a rapid change in MIC from a PMB susceptible to resistant phenotype
after a short incubation period (Fig. 2B). These findings indicate that. (A) TIVAR+ S. Typhimurium 14028 and TIVAR− S. Typhimurium var. 5 (04)-9639 were
medium for 3 cell generations; subsequently these cells were transferred back into MHB
vernight in MHB medium, and bacterial cells from the saturated culture were transferred
containing polymyxin B from at least three independent determinations. (C) The effect
myxin B in bacterial cell survival assays (Groisman et al., 1997). S. Typhimurium 14028
exposed to PMB (1 h) under I or NI conditions, with CFU determined on nonselective LB
pH 5.8). White bars (I/NI), growth (N-minimal medium with 10 μMMg2+ pH 5.8); drug
exposure (N-minimal medium with 10 μMMg2+ pH 5.8). Hatched bars (NI/NI), growth
olymyxin B] / CFU[no drug] × 100 at 1 h post drug exposure. Statistical significance for cell sur-
ed from at least 5 independent determinations. ***P b 0.001; limit of detection b 0.02%.
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does not require rapid cell division and mutational selection. Since
this resistance mechanism is rapidly reversible and induced under ex-
perimental conditions that simulate host microenvironments, we have
termed this mechanism TIVAR, transient in vivo antibiotic resistance.
Next, the number of resistant cells in the bacterial population was
evaluated as a function of environmental conditions in bacterial cell sur-
vival assays, wherein cell viability is monitored after drug treatment
(Groisman et al., 1997; Gunn and Miller, 1996). Our findings indicate
that more than 80% of the bacterial population survived a high-dose
PMB treatment (20 μg/ml) only if both prior growth and drug exposure
occurred in inducing (I/I) conditions (Fig. 2C); cell survival wasmarked-
ly decreased if either transpired in non-inducing conditions (I/NI; NI/I;
NI/NI). Together, these data indicate that TIVAR induction involves a
substantial portion of the bacterial population and requires both prior
cell and drug exposure under inducing conditions.
3.3. The role of the environment in microbial susceptibility to antibiotics
Since the PhoPQ/PmrAB regulons contribute to resistance to cationic
peptides via LPS remodeling of Gram-negative membranes (Chen and
Groisman, 2013; Gunn, 2008), we tested whether these regulatory
functions were required for the TIVAR phenotype. Introduction of
pmrA and/or phoP null mutations into TIVAR+ S. Typhimurium abro-
gated PMB resistance under inducing and non-inducing conditions;
whereas introduction of constitutively active mutations in pmrA orFig. 3. The role of the environment (Fe3+) in microbial susceptibility to antibiotics. (A) pmrAB
tations (pmrA505, phoQ24) were introduced into S. Typhimurium 14028. Bacteria were grown
dium fromat least three independent determinations. (B) Bacteriawere grown in LPMpH5.5m
plasmid containingwild-type sequences of the indicatedmutation. * denotes no growth in thep
pmrABP1 -72CNT, pmrBH152Y; F2 (human feces) pmrABP1 -72CNT, pmrBH152Y; F1 (human fece
phoQ P83L. Both B10 (human blood) and var. 5 (04)-9639 (cow GI) strains were complement
mutations were not found in pmrD, phoPQ, or pmrCAB, suggesting parental mutation(s) are w
(unbuffered) or MHB pH 5.5 media in the presence and absence of 100 μM FeSO4, and the p
determinations.phoQ (Groisman et al., 1997; Gunn and Miller, 1996; Roland et al.,
1993; Tamayo et al., 2005) resulted in high-level PMB resistance
under non-inducing conditions (Fig. 3A). None of these mutations
affected the induction of trimethoprim or ciprofloxacin resistance, sug-
gesting that the host microenvironment may influence microbial sus-
ceptibility through multiple regulatory pathways, each operating in
antibiotic-specific fashion.
The PmrAB regulatory system promotes resistance to toxic metals
and cationic peptides in response to ex vivo signals (e.g., high Fe3+),
which activate PmrB and downstream genes involved in Gram-
negative membrane remodeling (Wösten et al., 2000). Thus, we rea-
soned that some naturally occurring TIVAR− isolates could potentially
be converted to TIVAR+ under high Fe3+ conditions via stimulation
of the PmrAB regulon and resultant bypassing of inherent mutational
deficiencies in membrane stabilization. To test this hypothesis, we
screened a collection of Salmonella clinical isolates for susceptibility
to PMB under LPM pH 5.5 conditions. These studies revealed that
TIVAR− isolates represent a significant subset of natural Salmonella
populations derived from human and livestock infections (Heithoff
et al., 2008): S. Typhimurium (10/61), S. Newport (2/10), S. Enteritidis
(2/8), S. Dublin (0/8), S. Bovismorbificans (2/5), and S. Choleraesuis
(3/3). Subsequently, we assessed whether TIVAR− isolates could con-
vert to TIVAR+ under high Fe3+ conditions. Growth of TIVAR− S.
Typhimurium strains in LPM pH 5.5 medium in the presence of
100 μM FeSO4 resulted in high-level PMB resistance in 5 of 7 strains
tested; 2 of 7 strains exhibited no growth in the presence of 100 μMand phoPQ null (pmrA601::Tn10d-Kn, phoP102::Tn10d-Cm) and constitutively active mu-
in either LPM or MHB at pH 5.5 or pH 7 and MIC values were determined in the same me-
edium in thepresence and absence of 100 μMFeSO4, or in the presence of a complementing
resenceof 100 μMFeSO4 due to iron toxicity. GI; gastrointestinal. (03)-1516 (horse non-GI)
s) pmrABP21599GNA; F13 (human feces) pmrABP21408TNC,pmrC E415Q; F7 (human feces)
ed to TIVAR+ with recombinant PmrD+ sequences (Roland et al., 1994); corresponding
ithin other genes in the PhoPQ/PmrAB pathway. (C) Bacteria were grown in MHB pH 7.2
olymyxin B MIC was determined in the same medium from at least three independent
1174 J.Z. Kubicek-Sutherland et al. / EBioMedicine 2 (2015) 1169–1178FeSO4 due to iron toxicity (Fig. 3B). Complementation, genetic linkage,
and DNA sequence analyses revealed that all (7 of 7) TIVAR− strains
contained mutations within the PhoPQ/PmrAB regulatory pathway;
and TIVAR− strains contain similar or, in some cases, identical muta-
tions that have circulated among diseased animals and humans. These
findings suggest that conversion of TIVAR− strains to the TIVAR+phe-
notype may occur in high Fe3+ soil/water environments.
Next, we evaluated the role of iron in the susceptibility of microbes
to antibiotics in MHB, the standard medium used clinically for antimi-
crobial susceptibility testing. While growth of TIVAR+ and TIVAR− S.
Typhimurium strains in MHB in the presence of 100 μM FeSO4 resulted
in a mild increase in PMB resistance relative to MHB (2 vs. 0.5 μg/ml),
growth inMHB pH 5.5 medium in the presence of 100 μM FeSO4 result-
ed in amarked increase in PMB resistance relative toMHBpH5.5 (64 vs.
0.5–1 μg/ml) (Fig. 3C). These levels are similar to those exhibited upon
growth in LPM pH 5.5 medium. These findings suggest that drug resis-
tance may also be induced in iron-abundant conditions that may exist
within in vivo and ex vivo environs.
3.4. Bacteria Exhibit High-level Antibiotic Resistance Only in a Subset of
Host Tissues
The degree of antibiotic resistance as a function of growth within
cultured macrophages was evaluated using TIVAR+ and TIVAR− bac-
teria that have comparable virulence in a murine model of typhoid
fever (Heithoff et al., 2012). TIVAR+ Salmonella derived from infected
cultured macrophages exhibited high-level PMB resistance via MIC de-
termination in vitro, whereas TIVAR− Salmonella did not (Fig. 4A). Fur-
ther, PMB treatment of infected cultured macrophages showed that
internalized TIVAR+ bacteria were much more resistant to PMB than
TIVAR− bacteria (P b 0.001; Fig. 4B) (the inability of PMB to clear
TIVAR− bacteria is presumably due to relatively low intracellular activ-
ity of cationic antimicrobial peptides (Buyck et al., 2013; Carryn et al.,
2003)). These findings indicate that internalized TIVAR+ bacteria are
refractory to killing by PMB relative to bacteria that do not exhibit the
TIVAR phenotype.
Next, the degree of antibiotic resistance exhibited by bacteria de-
rived from infected mice was evaluated in a murine model of typhoid
fever. Mice were intraperitoneally infected with TIVAR+ or TIVAR−Fig. 4. Salmonella exhibit high-level antibiotic resistance within cultured macrophages and are
Typhimurium 14028 and TIVAR− S. Typhimurium var. 5 (04)-9639 derived from cultured RAW
containing polymyxin B (PMB) or nalidixic acid (NAL). MIC valueswere the result of 2 to 3 indep
the proliferation of TIVAR+ and TIVAR− Salmonellawithin cultured RAW264.7 murine macr
derived from 2 to 4 independent determinations performed in triplicate. Log transformed i
***P b 0.001.Salmonella, and bacteria derived from the tissues of septic mice were
assessed for antibiotic susceptibility via MIC determination in vitro.
TIVAR+ Salmonella exhibited high-level PMB resistance (MIC =
128–256 μg/ml) onlywhen derived froma subset of host tissues, includ-
ingmesenteric lymph nodes, lung, liver, spleen and gall bladder (Fig. 5).
In contrast, the TIVAR phenotypewas not manifested in TIVAR+ bacte-
ria derived from other host tissues and from biological samples routine-
ly used to detect bacterial infection (blood, feces, urine), or in TIVAR−
bacteria derived from all tissues and biological samples tested. Since cir-
culating PMB levels in treated patients and experimental rat infections
range from 0.5 to 2.5 mg/l (Omri et al., 2002; Sandri et al., 2013;
Zavascki et al., 2008), our findings indicate that TIVAR promotes drug
resistance at certain host sites even when drug levels in circulation of
mice are potentially 100 times higher than in treated patients.3.5. Antibiotic Treatment Fails to Control Bacterial Infection and Promotes
the Emergence of Drug-resistant Mutants
Polymyxin B is a last-line therapy to treat infections caused by
multidrug-resistant Gram-negative bacteria in critically ill patients
(Sandri et al., 2013; Zavascki et al., 2008). Thus, we evaluated whether
PMB treatment was able to control TIVAR+ Salmonella infection in a
murine model of typhoid fever. All untreated mice infected with
TIVAR+ or TIVAR− bacteria died within 5 days of infection (Fig. 6A).
PMB treated mice infected with TIVAR− bacteria survived at least
10 days post-infection, whereas all PMB treated mice infected with
TIVAR+ bacteria died within 7 days of infection (P b 0.001). Since the
PMB dose given (30 mg/kg/day) was 6 to 20-fold higher than that
used to treat human or experimental rat infections (1.5 to 5 mg/kg/day
(Abdelraouf et al., 2012; Bergen et al., 2012; Landman et al., 2008)),
human infection with TIVAR+ bacteria would likely not be controlled
by prescribed dosages. In contrast, ciprofloxacin (CIP) treated mice
infected with TIVAR+ Salmonella survived at least 10 days post-
infection at dosages used to treat human or experimental mouse infec-
tions (30 mg/kg/day (Fantin et al., 2009; Guillard et al., 2013)). These
data are consistentwith thebacterium's susceptibility to CIP inMIC test-
ing under LPMpH5.5 conditions (Fig. 1A), and the drug's established in-
tracellular activity (Carryn et al., 2003).refractory to killing by antibiotic treatment. (A) Antimicrobial susceptibility of TIVAR+ S.
264.7murinemacrophageswas evaluated via MIC determination on LPM pH 5.5 medium
endent determinations performed in triplicate. (B) Efficacy of antibiotic administration on
ophages (PMB, gentamicin [GNT]). Values given are the average intracellular CFU ± SEM
ntracellular CFU data were analyzed for statistical significance using ANOVA; *P b 0.05,
Fig. 5. Salmonella exhibit high-level antibiotic resistancewhen derived from a subset of host tissues and cells. BALB/cmicewere infectedwith TIVAR+ S. Typhimurium14028 or TIVAR− S.
Typhimurium var. 5 (04)-9639 (i.p. dose 103 CFU), and bacteria were derived from host tissues of septic mice. Antimicrobial susceptibility was assessed by MIC determination under
inducing conditions (LPM pH 5.5 medium). TIVAR+ S. Typhimurium MT2057 (kanamycin [KAN] resistant derivative of S. Typhimurium 14028) and TIVAR− S. Typhimurium var.
5 (04)-9639 (naturally resistant to chloramphenicol [CAM])were used in these studies. MIC determinations for these strains contained KAN (40 μg/ml) and CAM (10 μg/ml), respectively,
and were obtained from 3 to 13 mice per tissue/fluid. MLN, mesenteric lymph nodes.
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ing infection of the host (Giraud et al., 2001; Martinez and Baquero,
2000; Nilsson et al., 2004). Here, we compared the frequency at which
permanent PMB resistant mutants (PMBr) arise in Salmonella derived
from cell culture versus that from antibiotic-treated or untreated ani-
mals. TIVAR+ or TIVAR− Salmonella derived from overnight LB culture
(in vitro) or from the spleens of septic mice (in vivo), obtained from un-
treated (day 5) and treated animals (TIVAR+, day 7; TIVAR−, day 10),
were plated on LBmedium containing PMB. Both TIVAR+ and TIVAR−
bacteria derived from the spleens of untreated mice exhibited a 60-fold
increase in frequency of PMBrmutants relative to in vitro grownbacteriaFig. 6.Antibiotic treatment is ineffective at controlling Salmonella infection andpromotes the em
14028 or TIVAR− S. Typhimurium var. 5 (04)-9639 (i.p. dose 102 CFU)were treated (or mock-t
10 mice/cohort). Mouse survival was assessed for 10 days post-infection. Statistical significanc
0.001. (B) TIVAR+ or TIVAR− Salmonella derived from overnight LB culture (in vitro) or from
(TIVAR+, day 7; TIVAR−, day 10), were plated on LB medium containing PMB (16 μg/ml). TIV
and TIVAR− S. Typhimurium var. 5 (04)-9639 were used in these studies. Values given are the
rived from 10 independent determinations. NA (not applicable): successful antibiotic treatmen
animals. Log transformed intracellular PMBr mutation frequency data were analyzed for statist(Fig. 6B). Furthermore, TIVAR+bacteria exhibited an additional ~5-fold
increase in mutation frequency when derived from treated (day 7) ver-
sus untreated (day 5) mice (P b 0.001). This implies that the increased
lifespan of treatedmice allows for additional rounds of bacterial replica-
tion, selection, and mutagenesis, ultimately resulting in an increased
frequency of permanent drug-resistant mutants (note that successful
antibiotic treatment of mice infected with TIVAR− bacteria precluded
recovery of PMBr mutants from these animals (day 10)). DNA sequence
analysis revealed that all PMBr mutants derived from TIVAR+ bacteria
in vitro (10/10) and in vivo (4/4) harbor mutationswithin pmrAB genes,
which are known to confer PMB resistance via lipopolysaccharide (LPS)ergence of drug-resistantmutants. (A) BALB/cmice infectedwith TIVAR+ S. Typhimurium
reated) with a twice-daily PMB or ciprofloxacin dosing regimen (30mg/kg/day; i.p. route;
e for difference in proportions of animal survival was calculated using Chi-square; ***P b
the spleens of septic mice (in vivo), obtained from untreated (day 5) and treated animals
AR+ S. TyphimuriumMT2057 (kanamycin resistant derivative of S. Typhimurium 14028)
averagemutation frequency (no. of PMBr colonies/total no. of colonies plated)± SEM de-
t of mice infected with TIVAR− bacteria precluded recovery of PMBr mutants from these
ical significance using ANOVA; ***P b 0.001.
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Kawasaki, 2012). Together, these findings indicate that antibiotic treat-
ment fails to control bacterial infection caused by TIVAR+bacteria, and
promotes the emergence of permanent drug-resistant mutants due to
bacterial survival and growth during treatment.
4. Discussion
Since the discovery of penicillin by Alexander Fleming in 1928, anti-
biotic resistance has become widespread and plagues our standard of
care today. We have identified a mechanism of antibiotic resistance
(TIVAR) that promotes resistance in vivo at levels of drug that far exceed
clinical doses routinely used for treatment. This mechanism has been
overlooked in part because it is reversible and only operates within a
subset of host tissues and cells, whereby the host milieu induces
changes in the bacterium such that pathogens may become transiently
resistant to high doses of certain antibiotics. TIVAR leads to treatment
failure in animals, and may lead to patient treatment failure with the
emergence of drug-resistant mutants due to bacterial survival and
growth during antibiotic exposure. These findings call into question
standardizedMIC testing that has guided physician antibiotic treatment
practices and drug development for the last several decades as it may
not correlate with patient outcome.
Although the standard 7–10 day antibiotic treatment regimen is
usually sufficient to clear microbial infections, some patients fail to re-
spond and require prolonged therapy, higher dosing or alternative anti-
biotics. This is particularly confounding in cases involving immune
competent individuals where bacterial ID and AST results predict drug
sensitivity.Whydoes this occur andwhat are the possible implications?
Although bacteria may be susceptible to antibiotics in the laboratory,
certain host sites may present a unique biochemical environment that
induces changes in the bacterium so they become transiently resistant
to high doses of certain antibiotics (Fig. 7). This results in a large,
transiently-resistant bacterial population from which permanent
drug-resistant mutants may arise via standard mutational mechanisms.
Supporting this hypothesis, Salmonella exhibited PMB resistance only
when derived from a subset of host tissues (lung, liver, spleen), but
not from other host tissues or from biological samples routinely used
to detect bacterial infection (blood, feces, urine). PMB treatment failed
to control bacterial infection in a murine model of typhoid fever and
was associated with an increased frequency of permanent drug-
resistant bacteria. This was presumably due to the increased lifespan
of treated mice, allowing for additional rounds of bacterial replication,
selection, and mutagenesis during antibiotic exposure. Additionally,
due to cross resistance between polymyxins and host antimicrobialsFig. 7. TIVAR overview. (A) The standard 7–10 day antibiotic treatment regimen is sufficient t
ineffective at controlling bacterial proliferation as certain host microenvironments may stimu
doses of antibiotics. This creates a major bacterial population that is transiently resistant to ce
mechanisms.(Band and Weiss, 2014), exposure to host cationic antimicrobial pep-
tides may provide selective pressure for drug-resistant mutants to
arise as soon as a bacterial infection is established and long before anti-
biotic therapy is even started.
The TIVAR mechanism of resistance to cationic peptides is medi-
ated by the PhoPQ/PmrAB regulatory system. Phenotypic switching
from susceptibility to resistance was found to be more rapid than
that of resistance to susceptibility, providing a means for retention
of resistance during bacterial dissemination from permissive host
sites (e.g., macrophages) in treated animals. Thus, macrophages
may serve as potential reservoirs for persistent infections caused
by intracellular bacteria. Additionally, the presence of Fe3+ triggered
resistance in otherwise non-permissive conditions, indicating that
resistance induction is not limited to the macrophage phagosome,
but may also occur in iron-abundant environments that may exist
ex vivo (soil/water) or in vivo (stomach) after ingestion of iron-rich
foods (Wösten et al., 2000). This raises the possibility that resistance
may be inadvertently triggered by diet; underlying conditions in the
patient (e.g., iron overload during hemochromatosis (National
Institutes of Health, 2015)); or by clinical interventions that may
counteract drug efficacy (e.g., treatment of uncomplicated urinary
tract infections to lower the pH of urine via ascorbic acid administra-
tion (Carlsson et al., 2001)).
A large proportion of antimicrobial use is directed to therapeutic and
prophylactic use in livestock, which has been associated with the emer-
gence of multidrug-resistant bacteria that have disseminated world-
wide (Cloeckaert and Schwarz, 2001). As such, TIVAR has potential
negative impacts on livestock production, with an increased risk of zoo-
notic transmission of multidrug-resistant pathogens to humans where-
by therapeutic options would be even further constrained (Singer et al.,
2003; Wegener, 2012). Moreover, since the induction of resistance was
responsive to subtle changes in environmental conditions,management
practices and environmental conditions inherent to livestock produc-
tion have the potential to inadvertently trigger antibiotic resistance
and the emergence of multidrug-resistant mutants; e.g., diet; the use
of antibiotics in feeds as growth promotants; and/or exposure to envi-
ronmental variables that may induce TIVAR resistance (livestock
waste, subtherapeutic concentration of antimicrobials, and/or passage
through different classes of stock).
TIVAR was evident in pathogenic serotypes of Salmonella and
Yersinia, and similar mechanisms of resistance may be prevalent across
the microbial realm. While it is likely that evolution of TIVAR predates
antibiotic use, it is likely to play into the alarming rates of emerging an-
tibiotic resistant bacteria. Even in the most advanced hospitals, high
drug doses are given to infected patients without the knowledge thato clear most bacterial infections. (B) Antibiotic treatment of persistent infections may be
late changes in the bacterium that result in the induction of transient resistance to high
rtain antibiotics, from which drug-resistant mutants may arise via established mutational
1177J.Z. Kubicek-Sutherland et al. / EBioMedicine 2 (2015) 1169–1178the host milieu may render bacteria inherently resistant to the antibi-
otics prescribed to control them. Nonetheless, for physicians managing
cases where an antibiotic fails to clear an infection, rather than extend-
ing the current treatment or increasing the dose, a potentially more ef-
fective therapeutic option is prescription of another antibiotic indicated
for the suspected pathogen. Unfortunately, standard in vitro testing
methods may also inadvertently exclude antibiotics with potent effica-
cy, thereby unnecessarily limiting therapeutic options for multidrug-
resistant pathogens as has been recently shown with azithromycin
(Lin et al., 2015). Additionally, in vitro assessments of antibiotic resis-
tance mutation frequency are not accurate predictors of clinical resis-
tance (Thulin et al., 2015). Our findings support the use of host
models as an important adjunct approach for antibiotic drug develop-
ment and susceptibility testing, and may further help to modify current
treatment guidelines to improve therapeutic intervention and diminish
the emergence of multidrug-resistant pathogens.
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